BCAL Diagnostics (ASX:BDX) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


What is BCAL Diagnostics Notes Receivable?

BCAL Diagnostics ASX:BDX -5.33% Notes Receivable is A$0.00 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

BCAL Diagnostics Notes Receivable Related Terms

BCAL Diagnostics Notes Receivable Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Notes Receivable Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Notes Receivable
0.00 0.00 0.00 0.00

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCAL Diagnostics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Notes Receivable too high?
BCAL Diagnostics' current Notes Receivable is A$0.00 Mil.
How does BCAL Diagnostics' Notes Receivable compare to TMO and DHR?
BCAL Diagnostics' Notes Receivable of A$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Notes Receivable of A$0.00 Mil. The current Notes Receivable is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.